High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia

Clinical Cancer Research

Volumn 11, Issue 24, 2005, Pages 8644-8652

  Bergmann, Olav J ^a,b,c   Johansen, Julia S ^a   Klausen, Tobias W ^a   Mylin, Anne K ^a   Kristensen, Jørgen S ^c   Kjeldsen, Eigil ^c   Johnsen, Hans E ^a,d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b ESBJERG HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CREATININE; CYTARABINE; GLYCOPROTEIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; MITOXANTRONE; PROTEIN YKL 40; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOGENETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEPTICEMIA; SERUM; SURVIVAL TIME;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GLYCOPROTEINS; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 29344449079     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1317     Document Type: Article

References (57)

1. Russell NH. Biology of acute leukaemia. Lancet 1997;349:118-22.
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
3. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003; 3:89-101.
4. Estey EH. Prognostic factors in acute myeloid leukemia. Leukemia 2001;15:670-2.
5. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101:64-70.
6. Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993;32:949-55.
7. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993; 268:25803-10.
8. Shackelton LM, Mann OM, Millis AJT. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodelling. J Biol Chem 1995;270:13076-83.
9. Renkema GH, Boot RG, Au FL, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998;251:504-9.
10. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997;43:221-5.
11. Rehli M, Niller H-H, Ammon C, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 2003; 278:44058-67.
12. Houston DR, Recklies AD, Krupa JC, et al. Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes. J Biol Chem 2003;278:30206-12.
13. Fusetti F, Pijning T, Kalk KH, et al. Crystal structure and carbohydrate binding properties of the human cartilage glycoprotein-39. J Biol Chem 2003;278: 37753-60.
14. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002;62:4364-8.
15. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005; 65:1678-86.
16. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 2001; 98:15044-9.
17. Sjogren H, Meis-Kindblom JM, Orndal C, et al. Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma-cytogenetic, molecular genetic, and cDNA microarray analyses. Am J Pathol 2003;162:781-92.
18. Johansen JS, Williamson MK, Rice JS, et al. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992;7:501-12.
19. Morrison BW, Leder P. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994;9:3417-26.
20. Junker N, Johansen JS, Hansen LT, et al. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 2005;96:183-90.
21. Kirkpatrick RB, Emery JG, Connor JR, et al. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp Cell Res 1997; 237:46-54.
22. Verhoeckx KCM, Bijlsma S, de Groene EM, et al. A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification of biomarkers for macrophage maturation in the U937 cell line. Proteomics 2004;4:1014-28.
23. Volck B, Price PA, Johansen JS, et al. YKL-40, a mammalian member of the bacterial chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998;110; 351-60.
24. Baeten D, Boots AMH, Steenbakkers PGA, et al. Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium. Correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 2000;43:1233-43.
25. Junker N, Johansen JS, Andersen CB, et al. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 2005;48:223-31.
26. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 2002;365:119-26.
27. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-α. Biochem J 2004; 380:651-9.
28. Malinda KM, Ponce L, Kleinman HK, et al. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999;250:168-73.
29. Nishikawa KC, Millis AJT. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003;287:79-87.
30. Jensen BV, Johansen JS. Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003;9:4423-34.
31. Johansen JS, Christensen IJ, Riisbro R, et al. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence-free survival. Breast Cancer Res Treat 2003;80:15-21.
32. Cintin C, Johansen JS, Christensen IJ, et al. Serum YKL-40 and colorectal cancer. Br J Cancer 1999;79: 1494-9.
33. HØgdall EVS, Johansen JS, Kjaer SK, et al. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep 2003;10:1535-8.
34. Oehn H, HØgdall EVS, Johansen JS, et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand 2003; 82:287-93.
35. Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 2004;22:3330-9.
36. Johansen JS, Drivsholm L, Price PA, et al. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 2004; 46:333-40.
37. Brasso K, Christensen IJ, Johansen JS, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I and YKL-40 in patients with metastatic prostate carcinoma. Prostate. In press 2005.
38. Cintin C, Johansen JS, Christensen IJ, et al. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 2002;95: 267-74.
39. Nutt CL, Betensky RA, Brower MA, et al. YKL-40 is a differentiated diagnostic marker for histologic sub-types of high-grade gliomas. Clin Cancer Res 2005; 11:2258-64.
40. Bennet J, Catovsky D, Daniel MT, et al. Proposals for classification of acute leukaemias. A report of the French-American-British co-operative group. Br J Haematol 1996;33:451-60.
41. Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, et al. Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomised, double-blind, placebo-controlled trial. J Clin Oncol 1997;15:2269-74.
42. Bergmann OJ, Christiansen M, Laursen I, et al. Low levels of mannose-binding lectin do not affect occurrence of severe infections or durations of fever in acute myeloid leukaemia during remission induction therapy. Eur J Haematol 2003;70:91-7.
43. Grimwade D, Walker H, Oliver F, et al.The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 tiral. Blood 1998;92:2322-33.
44. Harvey S, Weisman M, O'Dell J, et al. Chondrex: new marker of joint disease. Clin Chem 1998;44:509-16.
45. Johansen JS, Krabbe KS, MØller K, et al. Circulating YKL-40 levels during human endotoxaemia. Clin Exp Immunol 2005;140:343-8.
46. Nordenbaek C, Johansen JS, Junker P, et al. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis 1999;180:1722-6.
47. Kronborg G, Østergaard C, Weis N, et al. Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated to the outcome of the disease. Scand J Infect Dis 2002; 34:323-6.
48. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80.
49. Johansen JS, Stoltenberg M, Hansen M, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology 1999;38:618-26.
50. Koutroubakis IE, Petinaki E, Dimoulios P, et al. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis 2003;18:254-9.
51. Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003;38:599-605.
52. Johansen JS, Baslund B, Garbarsch C, et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum 1999;42:2624-30.
53. Hashimoto S, Suzuki T, Dong H-Y, et al. Serial analysis of gene expression in human monocytes and macrophages. Blood 1999;94:837-44.
54. Suzuki T, Hashimoto S, Toyoda N, et al. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 2000;96: 2584-91.
55. Boot RG, van Achterberg AE, van Aken BE, et al. Strong induction of members of the chitinase family of proteins in atherosclerosis. Chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 1999;19: 687-94.
56. Johansen JS, Milman N, Hansen M, et al. Increased serum YKL-40 in patients with pulmonary sarcoidosis - a potential marker of disease activity? Resp Med 2005;99:396-402.
57. Ziegler-Heitbrock HWL. Heterogeneity of human blood monocytes: the CD14+CD16+ subpopulation. Immunol Today 1996;17:424-8.